Oslo-based Thor Medical has signed a three-year agreement to supply radium-224 and lead-212 to Medicines Discovery Catapult (MDC), a UK life science service for drug discovery. The isotopes will support MDC’s work to speed up the development of radiopharmaceutical cancer therapies in the UK.

SynAct Pharma has signed its first commercial partnership for its drug candidate resomelagon. Under the agreement, the Swedish company and the Brazilian pharmaceutical company Hipolabor will co-develop and commercialize the drug for the treatment of dengue in Brazil, one of the world’s largest dengue markets.

Finnish pharmaceutical company Orion has upgraded its full-year 2026 outlook for both net sales and operating profit, as royalty income has grown faster than expected so far this year.

Uppsala-based diagnostics company Gradientech has launched QuickMIC GN02, a new panel for its rapid antibiotic susceptibility testing (AST) system that gives results for hard-to-treat Gram-negative bacteria in 3 hours and 14 minutes. The panel is CE marked under the EU’s IVDR.

Norwegian medtech company Medistim reported record third-quarter revenue of NOK 210.0 million, up 25.9% from NOK 166.8 million a year earlier. Operating profit rose 55.7% to NOK 63.1 million, and the board decided on the company’s first quarterly dividend, NOK 2.50 per share.

Episurf Medical has signed a letter of intent with Canada’s Oligo Medic for the possible sale of its medical technology business, as the Swedish company shifts its focus to real estate.

The US Food and Drug Administration has approved Xbrane Biopharma’s Lucamzi (ranibizumab-blrz) as a biosimilar to Lucentis. The approval gives US patients a lower-cost option for treating wet age-related macular degeneration (AMD) and other serious eye conditions.

The US Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI, Alvotech’s biosimilar to Humira, that more than doubles drug substance output per batch at the company’s facility in Reykjavik.

Alvotech and its partner Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to the high-dose retinal disease drug Eylea 8 mg. According to the companies, it is the first known submission of its kind worldwide.

Researchers at Karolinska Institutet have been granted a total of SEK 59 million from the Swedish research council Formas for two new research programs on how climate change affects human health.

Forska!Sverige has established a new entrepreneurship award in memory of inventor and entrepreneur Leif Lundblad. The first recipient is Ulf Landegren, Professor of Molecular Medicine at Uppsala University, who has built several successful life science companies while helping other researchers do the same.

Karolinska Institutet researchers Tim Baker and Carl Otto Schell have received the Lancet–Elsevier Foundation Evidence to Impact Award for Essential Emergency and Critical Care (EECC), a set of 40 basic treatments for critically ill patients on regular hospital wards.